Ketamine has received FDA orphan drug designation for complex regional pain syndrome (CRPS). Other treatments for CRPS, including low dose naltrexone, have also been designated as orphan drugs. Additionally, several companies are working on developing treatments for CRPS, including a sublingual ketamine delivery platform and other pain medications.